Anamarija M. Perry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anamarija M. Perry has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Ramzan
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
11 shared publications - Aishwarya Gurumurthy
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
11 shared publications - Alec Chu
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
11 shared publications - Anna B. Owczarczyk
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
11 shared publications - Anthony D. Schmitt
Arima Genomics, San Diego, CA
11 shared publications - Arvind Emmanuel
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
11 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Demographic and clinical diagnostic information about DLBCL patient biopsies used for Hi-C and H3K27ac ChIP-Seq
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Demographic and clinical diagnostic information about DLBCL patient biopsies used for Hi-C and H3K27ac ChIP-Seq
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Significant peaks of sgRNA enrichment or depletion identified in sliding-window analysis of MYC locus tiling CRISPRi screens
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Significant peaks of sgRNA enrichment or depletion identified in sliding-window analysis of MYC locus tiling CRISPRi screens
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Experimental resources: Oligonucleotide sequences, cell line information, and whole genome sequencing data sources
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Experimental resources: Oligonucleotide sequences, cell line information, and whole genome sequencing data sources
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Supplementary figures S1-S7, showing additional information relevant to the corresponding main figure.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Supplementary figures S1-S7, showing additional information relevant to the corresponding main figure.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Analysis of NFR and gene–focused CRISPRi screens in 8 lymphoma cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Analysis of NFR and gene–focused CRISPRi screens in 8 lymphoma cell lines.
- 14 March 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 11
Primary diffuse large B-cell lymphoma of cauda equina: a rare and challenging diagnosis
Primary diffuse large B-cell lymphoma (DLBCL) of cauda equina is a very rare manifestation of neurolymphomatosis. A 52-year-old female presented with progressive symptoms of left lower extremity burning sensation. After initial conservative management with no improvement, MRI of the lumbosacral spine showed pathologic enhancement and thickening of cauda equina nerve roots. Examination of cerebrospinal fluid, coupled with flow cytometry, was diagnostic of DLBCL. Clinicians and pathologists should be aware of this unusual and challenging clinical presentation of DLBCL.
- 14 March 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 11
Primary diffuse large B-cell lymphoma of cauda equina: a rare and challenging diagnosis
Primary diffuse large B-cell lymphoma (DLBCL) of cauda equina is a very rare manifestation of neurolymphomatosis. A 52-year-old female presented with progressive symptoms of left lower extremity burning sensation. After initial conservative management with no improvement, MRI of the lumbosacral spine showed pathologic enhancement and thickening of cauda equina nerve roots. Examination of cerebrospinal fluid, coupled with flow cytometry, was diagnostic of DLBCL. Clinicians and pathologists should be aware of this unusual and challenging clinical presentation of DLBCL.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 3373759
Spontaneous Remission of Acute Myeloid Leukemia With Mutated NPM1 Following SARS‐CoV‐2 Infection
Acute myeloid leukemia (AML) with NPM1 mutation is the most common of the genetically defined AMLs in adults. Spontaneous remission (SR) of AML is very rare but well documented in the literature with < 40 reported cases in the last 25 years . SR of AML is usually short in duration, and most patients relapse in < 6 months . Causes of SR of AML are unclear, but most cases occurred in association with infection, including a few recently reported cases associated with SARS‐CoV‐2 infection. We report a unique case of a 77‐year‐old female with a 4‐year history of cytopenias prior to diagnosis of AML with mutated NPM1 , concurrent with an infection by SARS‐CoV‐2. She subsequently experienced a SR of AML with loss of the NPM1 mutation. After entering SR, the patient was initiated on treatment with subcutaneous azacitidine and venetoclax and has remained in remission for 44 months. Clinicians should be aware of this rare phenomenon and closely follow up these patients, as the SR of AML is usually of short duration.
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 3373759
Open AccessSpontaneous Remission of Acute Myeloid Leukemia With Mutated NPM1 Following SARS‐CoV‐2 Infection
Acute myeloid leukemia (AML) with NPM1 mutation is the most common of the genetically defined AMLs in adults. Spontaneous remission (SR) of AML is very rare but well documented in the literature with < 40 reported cases in the last 25 years . SR of AML is usually short in duration, and most patients relapse in < 6 months . Causes of SR of AML are unclear, but most cases occurred in association with infection, including a few recently reported cases associated with SARS‐CoV‐2 infection. We report a unique case of a 77‐year‐old female with a 4‐year history of cytopenias prior to diagnosis of AML with mutated NPM1 , concurrent with an infection by SARS‐CoV‐2. She subsequently experienced a SR of AML with loss of the NPM1 mutation. After entering SR, the patient was initiated on treatment with subcutaneous azacitidine and venetoclax and has remained in remission for 44 months. Clinicians should be aware of this rare phenomenon and closely follow up these patients, as the SR of AML is usually of short duration.
- Open Access
- 17 July 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-12
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
Primary testicular (PT) diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive lymphoma with distinct clinical and molecular characteristics. To identify prognostic biomarkers in PT-DLBCL, in this study we analyzed DNA and RNA samples of PT-DLBCL tumors from 206 patients using next-generation sequencing platforms and assays. Genetic alteration analysis found that multiple chromosomal copy number variations (CNVs), TP53 transcript mutations with high variant allele frequency, and MCD subtype had significantly adverse prognostic effects, whereas elevated microsatellite instability had a significantly favorable prognostic effect in PT-DLBCL. Targeted RNA-seq analysis identified a PTL gene expression signature by comparing PT-DLBCL with systemic DLBCL and revealed the heterogeneity within PT-DLBCL by unsupervised clustering, which classified PT-DLBCLs into a testicular lymphoma tumor (TLT) subtype and a microenvironment (ME) subtype. The TLT subtype featured upregulation of genes functioning in DNA damage response, DNA repair, chromatin remodeling, the cell cycle, and the nucleus, and was associated with significantly poorer patient survival and higher frequencies of MYD88 mutations, multiple CNVs, MCD subtype, bulk tumors, and elderly patients in the PT-DLBCL cohort. In contrast, the ME subtype distinctively featured upregulation of various signaling pathway genes involving the tumor microenvironment and downregulation of BTK and B-cell receptor signaling genes, and was associated with significantly better clinical outcome than the TLT subtype of PT-DLBCL independently of CNVs, MCD and MYD88 mutation and than systemic DLBCL. Moreover, genomic microRNA profiling analysis identified a PTL microRNA signature significantly differentially expressed between PT-DLBCL and systemic DLBCL patients and within the PT-DLBCL cohort, and PT-DLBCL patients with higher expression of 16 PTL microRNAs (14 are testicular tissue-specific) had significantly better survival. In summary, this study revealed the molecular heterogeneity in genetic abnormalities and expression profiles of coding genes and microRNAs within the PT-DLBCL entity, and identified significant prognostic biomarkers and PTL signatures.
- 17 July 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-12
Open AccessPrognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
Primary testicular (PT) diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive lymphoma with distinct clinical and molecular characteristics. To identify prognostic biomarkers in PT-DLBCL, in this study we analyzed DNA and RNA samples of PT-DLBCL tumors from 206 patients using next-generation sequencing platforms and assays. Genetic alteration analysis found that multiple chromosomal copy number variations (CNVs), TP53 transcript mutations with high variant allele frequency, and MCD subtype had significantly adverse prognostic effects, whereas elevated microsatellite instability had a significantly favorable prognostic effect in PT-DLBCL. Targeted RNA-seq analysis identified a PTL gene expression signature by comparing PT-DLBCL with systemic DLBCL and revealed the heterogeneity within PT-DLBCL by unsupervised clustering, which classified PT-DLBCLs into a testicular lymphoma tumor (TLT) subtype and a microenvironment (ME) subtype. The TLT subtype featured upregulation of genes functioning in DNA damage response, DNA repair, chromatin remodeling, the cell cycle, and the nucleus, and was associated with significantly poorer patient survival and higher frequencies of MYD88 mutations, multiple CNVs, MCD subtype, bulk tumors, and elderly patients in the PT-DLBCL cohort. In contrast, the ME subtype distinctively featured upregulation of various signaling pathway genes involving the tumor microenvironment and downregulation of BTK and B-cell receptor signaling genes, and was associated with significantly better clinical outcome than the TLT subtype of PT-DLBCL independently of CNVs, MCD and MYD88 mutation and than systemic DLBCL. Moreover, genomic microRNA profiling analysis identified a PTL microRNA signature significantly differentially expressed between PT-DLBCL and systemic DLBCL patients and within the PT-DLBCL cohort, and PT-DLBCL patients with higher expression of 16 PTL microRNAs (14 are testicular tissue-specific) had significantly better survival. In summary, this study revealed the molecular heterogeneity in genetic abnormalities and expression profiles of coding genes and microRNAs within the PT-DLBCL entity, and identified significant prognostic biomarkers and PTL signatures.
- Open Access
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Significant peaks of sgRNA enrichment or depletion identified in sliding-window analysis of MYC locus tiling CRISPRi screens
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Significant peaks of sgRNA enrichment or depletion identified in sliding-window analysis of MYC locus tiling CRISPRi screens
- Open Access
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Demographic and clinical diagnostic information about DLBCL patient biopsies used for Hi-C and H3K27ac ChIP-Seq
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
Demographic and clinical diagnostic information about DLBCL patient biopsies used for Hi-C and H3K27ac ChIP-Seq